Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer

This blog post is a review of the article cited above.

Introduction

Rectal cancer is a significant health issue, with approximately 53,200 projected deaths in the United States in 2020 alone. Traditionally, treatment for locally advanced rectal cancer (LARC) involves a combination of chemoradiotherapy and surgery, followed by additional chemotherapy. However, a recent approach known as total neoadjuvant therapy (TNT) is gaining attention. TNT aims to administer preoperative chemotherapy alongside chemoradiotherapy to improve patient outcomes by targeting micrometastases promptly. This blog examines the findings of a systematic review and meta-analysis comparing TNT with the standard chemoradiotherapy plus adjuvant chemotherapy (CRT plus A) regimen.

Objectives of the Study

The primary objective of the study was to determine whether TNT leads to improved patient outcomes compared to standard therapy. Specific outcomes measured included:

• Rate of pathologic complete response (PCR)
• Disease-free and overall survival
• Rates of sphincter-preserving surgery
• Need for ileostomy

Methodology

Data Sources

For this analysis, researchers utilized databases such as MEDLINE and Embase to identify relevant studies. This search was conducted up to July 1, 2020, focusing on trials published in English involving patients with LARC undergoing TNT or CRT plus A.

Study Selection Criteria

Included studies had to meet the following criteria:

• Randomized clinical trials or cohort studies
• Involvement of patients diagnosed with LARC
• Comparative outcomes between TNT and CRT plus A

Key Findings

After reviewing 2,165 reports, seven unique studies were selected for analysis, encompassing a total of 2,416 patients, with 1,206 receiving TNT. The following findings emerged:

• The median age of TNT recipients ranged from 57 to 69 years, with 58% to 73% being male.
• The pooled prevalence of PCR was significantly higher in the TNT group (29.9%) compared to the CRT plus A group (14.9%).
• TNT showed an odds ratio (OR) of 2.44 (with a 95% confidence interval [CI] of 1.99-2.98) for achieving a PCR.
• No statistically significant differences were noted between the two groups in terms of sphincter-preserving surgery or ileostomy rates.
• The analysis of disease-free survival indicated a notable improvement associated with TNT, with an OR of 2.07 (95% CI, 1.20-3.56).

Discussion

This study is the first systematic review and meta-analysis comparing TNT with conventional CRT plus A for treating LARC. The results suggest that TNT is associated with a significantly higher chance of achieving complete pathologic responses and better disease-free survival rates. However, no significant differences were found in certain surgical outcomes, leading to further questions about the long-term benefits of TNT.

Importance of Pathologic Complete Response

Pathologic complete response is an important prognostic marker in cancer treatment. Achieving PCR after neoadjuvant therapy indicates that patients have a reduced risk of local recurrence and improved survival outcomes. This study highlighted that a higher proportion of patients achieving PCR through TNT correlates with beneficial long-term results.

Watch-and-Wait Approach

With an increasing number of patients experiencing PCR, the watch-and-wait strategy, where patients are monitored without immediate surgery, is gaining traction. Some studies indicate promising outcomes for patients who achieve a clinical complete response, showing high rates of disease-free survival.

Future Directions

While current findings support TNT as a favorable approach, several areas require further investigation:

• Long-term effects of TNT versus traditional therapies on overall survival and disease recurrence.
• Identification of biomarkers that predict which patients will benefit most from TNT.
• Improved methodologies for monitoring patient outcomes when employing a watch-and-wait strategy.

Conclusion

Overall, total neoadjuvant therapy presents a promising strategy that may enhance outcomes for patients with locally advanced rectal cancer. The increased rates of pathologic complete response and suggested improvements in disease-free survival warrant further exploration. Nonetheless, the long-term implications of this treatment approach need carefully structured clinical trials to validate its effectiveness and establish standardized patient care protocols.